Showing 1,272 results

Filters Content type: News, Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven

Editor's pick
German Institute for Quality and Efficiency in Health Care
19 August 2016
Pharmaceutical industry

German agency criticises European programme for speeding some drug approvals

Editor's pick
STAT
18 August 2016
New & experimental HIV treatments

ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment

Editor's pick
ViiV press release
16 August 2016
New & experimental HIV treatments

Once-daily raltegravir works as well as twice-daily for initial HIV treatment

News
26 July 2016
New & experimental HIV treatments

Dolutegravir plus lamivudine dual therapy works well as initial HIV treatment

News
25 July 2016
New & experimental HIV treatments

Long-acting injectable drugs work well for HIV maintenance therapy

News
22 July 2016
The search for a cure

HIV will only be cured with combinations too, conference delegates hear

News
20 July 2016
New & experimental HIV treatments

Treatment Action Group: Pipeline Report 2016

Editor's pick
Treatment Action Group
15 July 2016
New & experimental HIV treatments

New integrase inhibitor bictegravir looks promising in early studies

News
6 July 2016
New & experimental HIV treatments

The HIV Treatment Pipeline

Editor's pick
Poz
28 June 2016
New & experimental HIV treatments

PRO 140 antibody injections maintain viral suppression in phase 2 study

News
28 June 2016
New & experimental HIV treatments

Gilead’s single tablet regimen Odefsey receives European marketing approval for HIV treatment

Editor's pick
PharmaBiz
27 June 2016
New & experimental HIV treatments

Investigational Integrase Inhibitor Bictegravir Safe and Effective Against HIV in Early Study

Editor's pick
The Body
21 June 2016
New & experimental HIV treatments

Frontier Biotech's Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

Editor's pick
Frontier Biotech press release
7 June 2016
Access to healthcare

Botswana gets GSK's modern HIV drug in largest ever Africa tender

Editor's pick
Reuters
3 June 2016
New & experimental HIV treatments

European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV

Editor's pick
Gilead press release
25 April 2016
Access to healthcare

ViiV Healthcare, Medicines Patent Pool Extend Licence for Dolutegravir to All Lower Middle-Income Countries

Editor's pick
ViiV Healthcare press release
25 April 2016
New & experimental HIV treatments

U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy

Editor's pick
Gilead press release
5 April 2016
New & experimental HIV treatments

Long-acting oral antiretroviral MK-8591 could represent 'paradigm shift' in HIV treatment and prophylaxis

News
1 April 2016
The search for a cure

Gene therapy snips HIV out of infected cells and makes uninfected cells resistant

News
30 March 2016
New & experimental HIV treatments

Combination inhibitor BMS-986197 demonstrates good activity against HIV in early study

News
18 March 2016
PrEP science

Maraviroc may work as PrEP in combination with another drug – but probably not by itself

News
3 March 2016
PrEP

San Francisco HIV providers: What did you learn at CROI 2016?

Editor's pick
BETA blog
3 March 2016
New & experimental HIV treatments

ABIVAX’s Novel Approach to Treat HIV Demonstrates Safety and Preliminary Anti-viral Activity in Phase IIa

Editor's pick
Abivax press release
2 March 2016